LAURIE LAVIN: Open Payments
NPI 1811435217 · TROY, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,755 in 186 payments from 10 companies in 2025. Trend: 2023 $4,418 · 2024 $4,271 · 2025 $3,755
Food & beverage: $3,749Education: $5
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 27 | $703 |
| Otsuka America Pharmaceutical, Inc. | 39 | $629 |
| Neurocrine BioSciences, Inc. | 23 | $523 |
| Janssen Pharmaceuticals, Inc | 25 | $459 |
| E.R. Squibb & Sons, L.L.C. | 22 | $383 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 17 | $372 |
| ABBVIE INC. | 15 | $309 |
| Teva Pharmaceuticals USA, Inc. | 13 | $239 |
| Axsome Therapeutics, Inc. | 4 | $108 |
| Corium, LLC | 1 | $30 |
Products named: ARISTADA, INGREZZA, COBENFY, CAPLYTA, INVEGA SUSTENNA, VRAYLAR, REXULTI, ABILIFY ASIMTUFII.
Industry payments across NY — which companies pay providers there.
